ES2039234T3 - Procedimiento para preparar acidos y esteres 1,2,3,4-tetrahidro-6-sustituido-4-aril (o heterociclo)-3-((amino sustituido) carbonil)-2-tioxo (u oxo)-5-pirimidincarboxilicos. - Google Patents

Procedimiento para preparar acidos y esteres 1,2,3,4-tetrahidro-6-sustituido-4-aril (o heterociclo)-3-((amino sustituido) carbonil)-2-tioxo (u oxo)-5-pirimidincarboxilicos.

Info

Publication number
ES2039234T3
ES2039234T3 ES198787302130T ES87302130T ES2039234T3 ES 2039234 T3 ES2039234 T3 ES 2039234T3 ES 198787302130 T ES198787302130 T ES 198787302130T ES 87302130 T ES87302130 T ES 87302130T ES 2039234 T3 ES2039234 T3 ES 2039234T3
Authority
ES
Spain
Prior art keywords
aryl
alkyl
substituted
hydrogen
piperazinilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787302130T
Other languages
English (en)
Inventor
Karnail Singh Atwal
George Charles Rovnyak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/008,037 external-priority patent/US4855301A/en
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2039234T3 publication Critical patent/ES2039234T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LOS COMPUESTOS DE LA FORMULA I MUESTRAN ACTIVIDAD CARDIOVASCULAR Y SUS SALES SON FARMACEUTICAMENTE ACEPTABLES, DONDE X ES OXIGENO O AZUFRE; R ES HIDROGENO, ALQUILO, CICLOALQUILO, ARILO O ARILALQUILO Y R1 ES HIDROGENO, ALQUILO, CICLOALQUILO, ARILO, HETEROCICLO II O HALO ALQUIL SUSTITUIDO, R Y R1 TOMADOS JUNTOS CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS SON 1-PIRROLIDINILO, 1-PIPERIDINILO, 1-AZEPINILO, 4-MORFOLINILO, 4-TIAMORFILINILO, 1-PIPERAZINILO, 4-ALQUIL- 1-PIPERAZINILO, 4-ARILALQUIL-1-PIPERAZINILO, 4-DIARILALQUIL-1-PIPERAZINILO O 1-PIRROLIDINILO, 1-PIPERIDINILO, O 1-AZEIPINILO SUSTITUIDOS CON ALQUILO, ALCOXI, ALQUILTIO, HALO, TRIFLUOROMETILO O HIDROXI; R2 ES HIDROGENO, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO (III) O HALO ALQUIL SUSTITUIDO; R3 ES HIDROGENO, ALQUILO, CICLOALQUILO, ARILO, HETERICICLO IV O HALO ALQUIL SUSTITUIDO, R4 ES ARILO O HETEROCICLO; R5 Y R6 SON CADA UNO INDEPENDIENTEMENTE HIDROGENO, ALQUILO, -(CH2)Q-ARILO O -(CH2)Q-CICLOALQUILO, Y1, Y2, Y3 TIENEN EL SIGNIFICADO DADO EN LA INVENCION, Q ES 0, 1, 2 O 3; M ES 0 UN NUMERO ESTERO DE 1 A 6; N ES 0 O UN NUMERO ENTERO DE 1 A 5; Y P ES UN NUMERO ENTERO DE 1 A 5.
ES198787302130T 1986-03-14 1987-03-12 Procedimiento para preparar acidos y esteres 1,2,3,4-tetrahidro-6-sustituido-4-aril (o heterociclo)-3-((amino sustituido) carbonil)-2-tioxo (u oxo)-5-pirimidincarboxilicos. Expired - Lifetime ES2039234T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83976786A 1986-03-14 1986-03-14
US91734986A 1986-10-09 1986-10-09
US07/008,037 US4855301A (en) 1986-10-09 1987-02-09 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters

Publications (1)

Publication Number Publication Date
ES2039234T3 true ES2039234T3 (es) 1993-09-16

Family

ID=27358497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787302130T Expired - Lifetime ES2039234T3 (es) 1986-03-14 1987-03-12 Procedimiento para preparar acidos y esteres 1,2,3,4-tetrahidro-6-sustituido-4-aril (o heterociclo)-3-((amino sustituido) carbonil)-2-tioxo (u oxo)-5-pirimidincarboxilicos.

Country Status (17)

Country Link
EP (1) EP0237347B1 (es)
JP (1) JPH0819113B2 (es)
KR (1) KR900005014B1 (es)
CA (1) CA1337655C (es)
DE (1) DE3770661D1 (es)
DK (1) DK169031B1 (es)
ES (1) ES2039234T3 (es)
FI (1) FI96683C (es)
GR (1) GR3002715T3 (es)
HU (1) HU206091B (es)
IE (1) IE60114B1 (es)
IL (1) IL81800A0 (es)
NO (1) NO871044L (es)
PH (1) PH27052A (es)
PL (1) PL153727B1 (es)
PT (1) PT84479B (es)
SU (1) SU1713437A3 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62267272A (ja) * 1986-05-15 1987-11-19 Sanwa Kagaku Kenkyusho Co Ltd 新規なジヒドロピリミジン化合物及びその塩、これらの製法並びに該化合物を有効成分とする循環器系作用剤
US4847379A (en) * 1987-11-30 1989-07-11 E. R. Squibb & Sons, Inc. 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
WO1996014846A1 (en) 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP0866708A4 (en) * 1995-11-16 1999-05-06 Synaptic Pharma Corp DIHYDROPIRIMIDINES AND THEIR USES
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
AU733883B2 (en) * 1997-02-04 2001-05-31 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
AU5568400A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
JP4897217B2 (ja) * 2002-09-12 2012-03-14 ダイアクロン ファーマシューティカルズ インコーポレイテッド カルシウムチャンネル遮断薬
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214778A (ja) * 1984-03-08 1985-10-28 Suntory Ltd Ν置換３，４−ジヒドロピリミジン誘導体ならびにその製造法および用途
HUT42077A (en) * 1985-06-03 1987-06-29 Squibb & Sons Inc Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
US4675321A (en) * 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
CA1275410C (en) * 1986-03-14 1990-10-23 Karnail S. Atwal 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo) -3-substituted-2-thioxo(or oxo)-5- pyrimidinecarboxylic acids and esters

Also Published As

Publication number Publication date
PH27052A (en) 1993-02-01
PL264629A1 (en) 1988-07-21
IE60114B1 (en) 1994-06-01
IL81800A0 (en) 1987-10-20
PL153727B1 (en) 1991-05-31
FI96683B (fi) 1996-04-30
PT84479B (pt) 1990-08-31
FI96683C (fi) 1996-08-12
GR3002715T3 (en) 1993-01-25
EP0237347A2 (en) 1987-09-16
HU206091B (en) 1992-08-28
EP0237347B1 (en) 1991-06-12
HUT43832A (en) 1987-12-28
KR900005014B1 (ko) 1990-07-16
FI871087A (fi) 1987-09-15
NO871044D0 (no) 1987-03-13
FI871087A0 (fi) 1987-03-12
NO871044L (no) 1987-09-15
SU1713437A3 (ru) 1992-02-15
PT84479A (en) 1987-04-01
JPH0819113B2 (ja) 1996-02-28
EP0237347A3 (en) 1988-11-02
KR870008856A (ko) 1987-10-21
CA1337655C (en) 1995-11-28
DK131887A (da) 1987-09-15
DK131887D0 (da) 1987-03-13
DK169031B1 (da) 1994-08-01
IE870633L (en) 1987-09-14
JPS62265271A (ja) 1987-11-18
DE3770661D1 (de) 1991-07-18

Similar Documents

Publication Publication Date Title
ES2039234T3 (es) Procedimiento para preparar acidos y esteres 1,2,3,4-tetrahidro-6-sustituido-4-aril (o heterociclo)-3-((amino sustituido) carbonil)-2-tioxo (u oxo)-5-pirimidincarboxilicos.
ES8607966A1 (es) Un procedimiento para preparar un derivado de dihidropiridina.
ES2062987T3 (es) Compuestos de actividad farmaceutica.
UA27238C2 (uk) Індолінові похідні, а також їх фармацевтично прийнятні солі, що є антагоністами вазопресинових v1-рецепторів, спосіб їх одержання, проміжні продукти і фармацевтична композиція
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
DE69636086D1 (de) Sauerstoff enthaltende heterocyclische verbindungen
ES2063153T3 (es) Amino-4 quinoleinas y naftiridinas, su procedimiento de preparacion y su aplicacion como medicamentos.
PT76450B (de) Spiro/4.(3+n)-2-aza-3-carbonsaeure-derivate verfahren zu ihrer herstellung diese enthaltende mittel und ihre verwendung
MX9707053A (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion, y composiciones farmaceuticas que contienen estos compuestos.
CO4560551A1 (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion
IS4133A (is) Aðferð við framleiðslu á nýjum afleiðum af 3-hýdroxýantraniliksýru og milliefni við framleiðslu þeirra
CO4290299A1 (es) Derivados de 1,5-benzodiazepina
ES453162A1 (es) Un procedimiento para la obtencion de compuestos heteroci- clicos.
ES8402839A1 (es) Procedimiento para la obtencion de nuevos poliazaheterociclicos policiclicos.
ATE46147T1 (de) 4-(nitrophenyl)-tetrahydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
AR247737A1 (es) Un procedimiento para la fabricacion de compuestos.
CO5031252A1 (es) Compuestos
ES2052206T3 (es) Procedimiento de preparacion de nuevos derivados de benzotiazolinona y las composiciones farmaceuticas que los contienen.
NO864760D0 (no) Nye fluorholdige 1,4-dihydropyridiner, fremgangsmaate til deres fremstilling, samt deres anvendelse som legemiddel.
DK1149079T3 (da) Tetrahydroisoquinolinalkanolderivater og farmaceutiske præparater indeholdende samme
DK443484A (da) 7,8,9,10-tetrahydro-6h-di-(b,d)-pyranyloxyaminopropanoler, syreadditionssalte heraf og fremgangsmaade til fremstilling af forbindelserne

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 237347

Country of ref document: ES